<!DOCTYPE html>
<html>
    <head>
        <title>HP | Entrepreneurship | iGem Winter Project</title>
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <link rel="icon" type="image/png" href="../../static/img/favicon.ico">
        <script type="module" src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.esm.js"></script>
        <script nomodule src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.js"></script>
        <link rel="stylesheet" href="../../static/css/basic.css">
        <link rel="stylesheet" href="../../static/css/load.css">
        <link rel="stylesheet" href="../../static/css/pages.css">
        <link rel="stylesheet" href="../../static/css/components.css">
        <style>
            .quote {
                font-size: 20px;  /* zoom font size */
            }
        </style>
    </head>
    <body>
        <!-- scroll progress bar -->
        <div class="scroll-progress"></div>
        
        <!-- Loading cast -->
        <div class="loading-container">
            <div class="loading-spinner-image">
                <img src="../../static/img/loading.svg" alt="Loading...">
            </div>
            <div class="loading-text">Loading...</div>
        </div>

        <div class="top_bar">
            <div class="menu_btn">
                <ion-icon name="menu-outline"></ion-icon>
            </div>
            <div class="logo_wrap">
                <a href="../../index.html"><img id="team_logo" src="../../static/img/logo-apart-text.svg" alt=""></a>
            </div>
            <div class="menu_wrap">
                <div id="project" class="menu_item">
                    <div class="title">Project<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../description.html">Description</a></li>
                        <li><a href="../design.html">Design</a></li>
                        <li><a href="../safety.html">Safety</a></li>
                    </ul>
                </div>
                <div id="wetlab" class="menu_item">
                    <div class="title">Wet Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../wetlab/engineering.html">Engineering</a></li>
                        <li><a href="../wetlab/construction.html">Construction</a></li>
                        <li><a href="../wetlab/protocol.html">Protocol</a></li>
                        <li><a href="../wetlab/parts.html">Parts</a></li>
                    </ul>
                </div>
                <div id="drylab" class="menu_item">
                    <div class="title">Dry Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../drylab/model&software.html">Model & Software</a></li>
                        <li><a href="../drylab/hardware.html">Hardware</a></li>
                    </ul>
                </div>
                <div id="human" class="menu_item">
                    <div class="title">Human Practice<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./overview.html">Overview</a></li>
                        <li><a href="./education.html">Education</a></li>
                        <li><a href="./entrepreneurship.html">Entrepreneurship</a></li>
                        <li><a href="./integrated.html">Integrated Human Practices</a></li>
                        <li><a href="./inclusivity.html">Inclusivity</a></li>
                        <li><a href="./sustain.html">Sustainable Development</a></li>
                        <li><a href="./ethical.html">Ethical Framework</a></li>
                    </ul>
                </div>
                <div id="team" class="menu_item">
                    <div class="title">Team<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../team/attributions.html">Attributions</a></li>
                        <li><a href="../team/member.html">Member</a></li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Page Title Background -->
        <div class="page-title-bg">
            <div class="bg-image" style="background-image: url('../../static/img/hp-overview/overview.png')"></div>
            <div class="overlay"></div>
            <div class="title-content">
                <h1>Entrepreneurship</h1>
            </div>
        </div>

        <!-- Main content wrapper -->
        <div class="main">
            <!-- Sidebar wrapper -->
            <div class="sidebarBg">
                <div class="sidebar">
                    <div class="sidebar-collapse-btn">
                        <ion-icon name="chevron-back-outline"></ion-icon>
                    </div>
                    
                    <div class="t1">
                        <span>Market Analysis</span>
                        <div class="t2">
                            <a href="#pestel">PESTEL Analysis</a>
                            <a href="#competitive">Competitive Analysis</a>
                            <a href="#swot">SWOT Analysis</a>
                            <a href="#cooperative">Potential partners</a>
                            <a href="#investment">Source of investment</a>
                        </div>
                    </div>
                    <div class="t1">
                        <span>Marketing and Implementation Strategy</span>
                        <div class="t2">
                            <a href="#request-analysis">Analysis of User Requests</a>
                            <a href="#marketing-strategy">Marketing Strategy</a>
                            <a href="#implementation">Implementation Strategy</a>
                        </div>
                    </div>
                    <div class="t1">
                        <span>Project Risk Analysis</span>
                        <div class="t2">
                            <a href="#deterministic">Deterministic Risk</a>
                            <a href="#uncertainty">Uncertainty Risk</a>
                        </div>
                    </div>
                    <div class="t1">
                        <a href="#references">References</a>
                    </div>
                </div>
            </div>

            <!-- sidebar expand button -->
            <div class="sidebar-expand-btn">
                <ion-icon name="chevron-forward-outline"></ion-icon>
            </div>

            <!-- Content area -->
            <div class="content">

                <section id="introduction">
                    <blockquote class="quote">
                        "Make technology accessible, make the business flourish"
                        <div class="quote-source">
                            - ClearCats Â® redefines the future of eye care.                        </div>
                    </blockquote>

                    <p>In the entrepreneurship sector, we have laid a solid foundation for the monetization of the project through systematic market analysis and accurate strategic planning. We used <strong>PESTEL analysis</strong>, <strong>Porter Five Force model</strong>, <strong>SWOT analysis</strong>, and other tools to comprehensively evaluate the market environment, competition landscape, and potential partners to ensure that the decision is scientific and forward-looking. In terms of financing, we have formulated a multi-stage investment strategy covering <strong>seed rounds to IPO</strong>, accurately matching the capital needs of different stages of development to ensure that the project has sufficient capital support from prototype development to global market expansion.</p>

                    <p>We focus on the two core groups of cataract patients and contact lens users, clarify value propositions, innovate promotion methods, and combine <strong>B2B and B2C</strong> channels, to expand product coverage. We enhance brand influence through authoritative endorsement, digital marketing, and public welfare linkage and create a reliable product image. We have planned a phased promotion path from pilot to globalization, built a partner ecosystem covering research and development, production, and public welfare, and improved the user support system to ensure continuous optimization and user satisfaction after launching the product.</p>

                    <p>In short, our work in the entrepreneurship section not only focuses on <strong>technological innovation</strong>, but also pays more attention to the dual realization of <strong>commercial feasibility</strong> and <strong>social value</strong>, striving to make every lens a step towards changing the world.</p>
                </section>


                <!-- <section id="market-analysis"> -->
                <h1>Market Analysis</h1>
                <section id="pestel">
                    <h2>PESTEL Analysis</h2>
                        
                    <div class="note-box">
                        <p><strong>Note:</strong> The following types of analysis are not from professional sources. When the actual project is implemented, it is necessary to seek help and support from the School of Economics. In the following attachment, I listed a series of experts, professors, and researchers that can be considered for advice, or if needed, we could seek analysis from graduate and doctoral students in the School of Economics. Multiple-party contact increases the possibility of finding help (Attachment 1).</p>
                    </div>

                    <div class="table-container">
                        <table>
                            <caption>PESTEL Analysis of ClearCats Project</caption>
                            <thead>
                                <tr>
                                    <th>Dimension</th>
                                    <th>Analyze content</th>
                                    <th>Opportunities and challenges</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Political</strong></td>
                                    <td><strong>Policy support:</strong> China's "14th Five-Year Plan" focuses on supporting biomedical innovation. Hangzhou's "Eagle Plan" may provide entrepreneurial funding.<br><br>
                                    <strong>Regulatory barriers:</strong> the approval cycle of the third category of medical apparatus is long (3-5 years), and it needs to be strictly reviewed by the National Medical Products Administration (NMPA).</td>
                                    <td>
                                        <strong>Opportunity:</strong> Accelerate approval through green channel.<br>
                                        <strong>Challenge:</strong> High compliance costs.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Economic</strong></td>
                                    <td><strong>Market size:</strong> The global ophthalmic drug market is expected to reach 46 billion dollars by 2025, and China's annual growth rate will exceed 15%<sup><a href="#ref8"></a>[8]</a> <a href="#ref9">[9]</a></sup>.<br><br>
                                    <strong>Cost pressure:</strong> Patients in developing countries have limited payment ability and need to reduce costs through large-scale production.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Potential for medical insurance coverage.<br>
                                        <strong>Challenge:</strong> High price sensitivity.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Social</strong></td>
                                    <td><strong>Aging trend:</strong> The proportion of the population over 60 years old in China has reached 20%, and the incidence of cataracts increases significantly with age.<br><br>
                                    <strong>Increased health awareness:</strong> Consumers' preference for non-invasive treatments has increased.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Precise positioning of the elderly market.<br>
                                        <strong>Challenge:</strong> Insufficient primary medical education.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Technological</strong></td>
                                    <td><strong>Breakthrough in synthetic biology:</strong> CRISPR engineering bacteria, targeted delivery technology, and other synthetic biology methods have matured.<br><br>
                                    <strong>Competing product threat:</strong> Novartis, Alcon and other pharmaceutical companies layout nano eye drops, but lack of long-term sustained-release solutions.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Technological differentiation.<br>
                                        <strong>Challenge:</strong> Patent barriers need to be broken through.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Environmental</strong></td>
                                    <td><strong>Sustainable production:</strong> Hydrogel materials must meet biodegradable standards to avoid microplastic pollution.<br><br>
                                    <strong>Carbon footprint management:</strong> Hangzhou Pharmaceutical Port Town requires companies to pass green factory certification.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Environmental protection brand premium.<br>
                                        <strong>Challenge:</strong> High cost of degradable materials.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Legal</strong></td>
                                    <td><strong>Biosafety Law:</strong> Engineering bacteria must meet the dual physical packaging requirements of the Biosafety Law.<br><br>
                                    <strong>Intellectual property rights:</strong> Need to lay out core patents (such as RNF114 targeted modification technology).</td>
                                    <td>
                                        <strong>Opportunity:</strong> Policy compliance enhances trust;<br>
                                        <strong>Challenge:</strong> Complex international patent layout.
                                        </td>
                                    </tr>
                                </tbody>
                        </table>
                        <div class="table-note">
                            Data sources: Market research and industry reports [8][9]
                        </div>
                    </div>
                </section>

                <section id="competitive">
                    <h2>Competitive Analysis Based on Porter's Five Forces Model</h2>

                    <div class="five-forces-diagram">
                        <div class="center-circle">
                            <span>Five Forces<br>Model</span>
                        </div>
                        <div class="force-circle top">
                            <span>Threat of<br>New<br>Entrants</span>
                        </div>
                        <div class="force-circle right">
                            <span>Threat of<br>Substitutes</span>
                        </div>
                        <div class="force-circle bottom-right">
                            <span>Bargaining<br>Power of<br>Buyers</span>
                        </div>
                        <div class="force-circle bottom-left">
                            <span>Bargaining<br>Power of<br>Suppliers</span>
                        </div>
                        <div class="force-circle left">
                            <span>Rivalry<br>Among<br>Existing<br>Competitors</span>
                        </div>
                    </div>

                    <style>
                        .five-forces-diagram {
                            position: relative;
                            width: 600px;
                            height: 600px;
                            margin: 50px auto;
                        }

                        .force-circle, .center-circle {
                            position: absolute;
                            background: #f0f0f0;
                            border-radius: 50%;
                            display: flex;
                            align-items: center;
                            justify-content: center;
                            text-align: center;
                            font-size: 16px;
                            transition: all 0.3s ease;
                        }

                        .center-circle {
                            width: 120px;
                            height: 120px;
                            background: #666;
                            color: white;
                            left: 50%;
                            top: 50%;
                            transform: translate(-50%, -50%);
                            z-index: 2;
                        }

                        .force-circle {
                            width: 150px;
                            height: 150px;
                        }

                        .top {
                            left: 50%;
                            top: 50px;
                            transform: translateX(-50%);
                            background: #ffdd99;
                        }

                        .right {
                            right: 50px;
                            top: 45%;
                            transform: translateY(-50%);
                            background: #ddb0dd;
                        }

                        .bottom-right {
                            right: 120px;
                            bottom: 80px;
                            background: #fff1a2;
                        }

                        .bottom-left {
                            left: 120px;
                            bottom: 80px;
                            background: #87ceeb;
                        }

                        .left {
                            left: 50px;
                            top: 45%;
                            transform: translateY(-50%);
                            background: #d4baef;
                        }

                        .force-circle:hover {
                            transform: scale(1.1);
                            background: #ffdada;
                        }

                        .top:hover {
                            transform: translateX(-50%) scale(1.1);
                            background: #ffdada;
                        }

                        .right:hover, .left:hover {
                            transform: translateY(-50%) scale(1.1);
                            background: #daf6ff;
                        }

                        .five-forces-diagram::before {
                            content: '';
                            position: absolute;
                            width: 60%;
                            height: 60%;
                            left: 50%;
                            top: 50%;
                            transform: translate(-50%, -50%);
                            border: 2px solid #ccc;
                            border-radius: 50%;
                            z-index: -1;
                        }
                    </style>

                    <!-- æ·»å äºåæ¨¡ååæè¡¨æ ¼ -->
                    <div class="table-container" style="width: 95%; margin: 20px auto;">
                        <table style="width: 100%;">
                            <caption>Porter's Five Forces Analysis of ClearCats Project</caption>
                            <thead>
                                <tr>
                                    <th style="width: 15%;">Five forces dimension</th>
                                    <th style="width: 35%;">Analyze content</th>
                                    <th style="width: 15%;">Threat level to the project</th>
                                    <th style="width: 35%;">Response strategies</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Rivalry among existing competitors</td>
                                    <td>
                                        <strong>Main competitors:</strong> traditional cataract surgery (Aier Eye Hospital, Novartis), nano eye drops (such as Novartis' Xiidra).<br><br>
                                        <strong>Competition focus:</strong> treatment cost, convenience, safety.<br><br>
                                        <strong>Status:</strong> Surgery is the gold standard, but the quota is uneven; the effect of eye drops is limited.
                                    </td>
                                    <td>Medium to high</td>
                                    <td>Differentiated competition: Focus on "non-surgical + long-acting sustained-release", avoid direct competition with the surgical market, and focus on developing countries and contact lens users.</td>
                                </tr>
                                <tr>
                                    <td>Bargaining power of suppliers</td>
                                    <td>
                                        <strong>Key suppliers:</strong> bio-hydrogel materials (PVA/hyaluronic acid), engineered bacterial chassis (Shuffle Escherichia coli), fluorescent protein (Crimson).<br><br>
                                        <strong>Supplier concentration:</strong> Material suppliers are scattered, and engineering technology relies on cooperation with universities.
                                    </td>
                                    <td>Low</td>
                                    <td>Vertical integration: Collaborate with the School of Materials Science and Technology at Zhejiang University to develop self-developed hydrogels and reduce external dependence.</td>
                                </tr>
                                <tr>
                                    <td>Bargaining power of buyers</td>
                                    <td>
                                        <strong>Hospitals/clinics:</strong> price-sensitive to innovative medical apparatus, but demand is rigid (developing countries urgently need alternatives).<br><br>
                                        <strong>Consumers:</strong> Individual users are price-sensitive, but can be bound to medical insurance or public welfare subsidies.
                                    </td>
                                    <td>Medium</td>
                                    <td>Tiered pricing: Hospitals purchase at high prices (covering R & D costs), while developing countries provide a public welfare version (simplifying functions).</td>
                                </tr>
                                <tr>
                                    <td>Threat of substitutes</td>
                                    <td>
                                        <strong>Direct substitution:</strong> gene therapy (such as CRISPR editing of lens cells), stem cell regeneration technology (still in the laboratory stage).<br><br>
                                        <strong>Indirect substitution:</strong> upgraded version of traditional eye drops (such as nanoliposome delivery).
                                    </td>
                                    <td>Low to medium</td>
                                    <td>Technical Competitive Edge: Accelerate patent layout (6 core patents have been planned), establish a dual barrier of "slow-release technology + engineering bacteria".</td>
                                </tr>
                                <tr>
                                    <td>Threat of new entrants</td>
                                    <td>
                                        <strong>Entry barriers:</strong> three types of medical apparatus approval (3-5 years), synthetic biology technology threshold, large-scale production costs.<br><br>
                                        <strong>Potential entrants:</strong> Multinational pharmaceutical companies (such as Johnson & Johnson and Bausch & Lomb) may enter through acquisitions or generics.
                                    </td>
                                    <td>Medium</td>
                                    <td>First-mover advantage: Seize the market through rapid clinical trials (in conjunction with Hangzhou Food and Drug Administration's green channel) and bind research and development resources from universities.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </section>

                <section id="swot">
                    <h2>SWOT Analysis</h2>
                    
                    <div class="swot-container">
                        <div class="swot-grid">
                            <div class="swot-item strengths">
                                <h3 class="swot-title">Strengths</h3>
                                <div class="swot-letter">S</div>
                            </div>
                            <div class="swot-item weaknesses">
                                <h3 class="swot-title right-title">Weaknesses</h3>
                                <div class="swot-letter left-letter">W</div>
                            </div>
                            <div class="swot-item opportunities">
                                <h3 class="swot-title">Opportunities</h3>
                                <div class="swot-letter">O</div>
                            </div>
                            <div class="swot-item threats">
                                <h3 class="swot-title right-title">Threats</h3>
                                <div class="swot-letter left-letter">T</div>
                            </div>
                        </div>
                    </div>

                    <style>
                        .swot-container {
                            width: 95%;
                            margin: 2em auto;
                            padding: 20px;
                        }

                        .swot-grid {
                            display: grid;
                            grid-template-columns: repeat(2, 1fr);
                            gap: 20px;
                            margin: 0 auto;
                        }

                        .swot-item {
                            padding: 25px;
                            border-radius: 20px;
                            position: relative;
                            min-height: 200px;
                            overflow: hidden;
                        }

                        .swot-item h3 {
                            margin-top: 0;
                            font-size: 1.8em;
                            font-weight: bold;
                            margin-bottom: 1em;
                        }

                        .swot-letter {
                            position: absolute;
                            font-size: 4em;
                            color: rgba(0, 0, 0, 0.15);
                            font-weight: normal;
                            bottom: 20px;  /* ç»ä¸åºé¨ä½ç½® */
                        }

                        /* Sçä½ç½® */
                        .strengths .swot-letter {
                            right: 40px;
                            bottom: 40px;
                        }

                        /* Wçä½ç½® */
                        .weaknesses .swot-letter {
                            left: 40px;
                            bottom: 40px;
                        }

                        /* Oçä½ç½® */
                        .opportunities .swot-letter {
                            right: 40px;
                            bottom: 40px;
                        }

                        /* Tçä½ç½® */
                        .threats .swot-letter {
                            left: 40px;
                            bottom: 80px;
                            top: 50%;
                        }

                        .swot-title {
                            margin: 0;
                            padding-left: 20px;
                            font-size: 2em;
                            font-weight: normal;
                            color: #666;
                            font-family: 'Comic Sans MS', cursive;
                        }

                        .right-title {
                            text-align: right;
                            padding-right: 20px;
                            padding-left: 0;
                        }

                        .left-letter {
                            left: 40px;
                            right: auto;
                            bottom: auto;
                            top: 50%;
                        }

                        .strengths {
                            background-color: rgba(176, 224, 230, 0.3);  /* æµèè² */
                        }

                        .weaknesses {
                            background-color: rgba(255, 218, 185, 0.3);  /* æµæ©è² */
                        }

                        .opportunities {
                            background-color: rgba(144, 238, 144, 0.3);  /* æµç»¿è² */
                        }

                        .threats {
                            background-color: rgba(255, 182, 193, 0.3);  /* æµçº¢è² */
                        }

                        /* ååºå¼è®¾è®¡ */
                        @media (max-width: 1000px) {
                            .swot-grid {
                                grid-template-columns: 1fr;
                            }
                        }
                    </style>
                    
                    <div class="table-container">
                        <table>
                            <caption>Internal Factors Analysis</caption>
                            <thead>
                                <tr>
                                    <th>Strengths</th>
                                    <th>Disadvantages (Weaknesses)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>The world's first "engineered bacteria + contact lenses" treatment platform</td>
                                    <td>The stability of engineering bacteria needs to be optimized, mainly in terms of the duration of use of a single pair of contact lenses</td>
                                </tr>
                                <tr>
                                    <td>Multiple indications for expansion (dry eye, glaucoma)</td>
                                    <td>Whether the treatment is effective needs further experimental verification</td>
                                </tr>
                                <tr>
                                    <td>Relying on Zhejiang University's industry-university-research resources</td>
                                    <td>Complex mass production process</td>
                                </tr>
                                <tr>
                                    <td></td>
                                    <td>Insufficient international patent layout</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>

                    <div class="table-container">
                        <table>
                            <caption>External Factors Analysis</caption>
                            <thead>
                                <tr>
                                    <th>Opportunities</th>
                                    <th>Threats</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Aging is intensifying, and the number of patients is increasing</td>
                                    <td>Industry giants lay and have the monopoly on the eye drops market</td>
                                </tr>
                                <tr>
                                    <td>Non-surgical needs in developing countries are urgent</td>
                                    <td>High European Union compliance costs</td>
                                </tr>
                                <tr>
                                    <td>SDGs drive inclusive healthcare investment</td>
                                    <td>Patients' doubts about live engineering bacteria</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </section>

                <section id="cooperative">
                    <h1>Potential partners</h1>
                    <!-- Content sections will go here -->

                    <p>planning to cooperate deeply with a certain enterprise, below are the enterprises that we might look into:</p>

                    <div class="table-container">
                        <table>
                            <caption>Potential Strategic Partners</caption>
                            <thead>
                                <tr>
                                    <th>Type</th>
                                    <th>Company/Organization</th>
                                    <th>Cooperation Direction</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td rowspan="2">Pharmaceutical Companies</td>
                                    <td><a href="https://www.eastchinapharm.com/en" target="_blank">Huadong Medicine</a> (Hangzhou)</td>
                                    <td>Jointly develop ophthalmic drug delivery systems and share clinical trial resources.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://www.venusmedtech.com/" target="_blank">Qiming Medical</a> (Hangzhou Medical Port)</td>
                                    <td>With the help of its medical apparatus industrialization experience, accelerate product landing.</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">Contact Lens Manufacturers</td>
                                    <td><a href="https://www.acuvue.com.cn/" target="_blank">Johnson & Johnson</a></td>
                                    <td>Technology licensing cooperation, integrating its global distribution network.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://www.bausch.com/" target="_blank">Bausch & Lomb</a></td>
                                    <td>Jointly launched the "therapeutic contact lens" brand to seize the high-end market.</td>
                                </tr>
                                <tr>
                                    <td>Research Institutions</td>
                                    <td>
                                        <a href="http://www.cmm.zju.edu.cn/cmmenglish/" target="_blank">Zhejiang University School of Medicine</a> 
                                        and 
                                        <a href="https://en.z2hospital.com/" target="_blank">The Second Affiliated Hospital Zhejiang University</a>
                                        (which is the most prominent among all affiliated hospitals in ophthalmology)
                                    </td>
                                    <td>Obtain clinical data, understand the market, and conduct preclinical research.</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">Investment Institutions</td>
                                    <td><a href="https://www.hillhouseinvestment.com/" target="_blank">Hillhouse Capital</a></td>
                                    <td>Focusing on early-stage investment in medical technology, potential A-round lead investor.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://hic.zju.edu.cn/" target="_blank">ZJU-Hangzhou Global Scientific and Technological Innovation Center</a></td>
                                    <td>Provide funds in the early stages of our project.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>

                </section>

                <section id="investment">
                    <h2>Source of Investment</h2>
                    <p>To ensure that the funding needs of the project are met at different stages of development, we have designed diversified financing paths. In the early stage (seed round), we will seek funding from <strong>Zhejiang University</strong> Alumni Fund (such as Zhejiang University Network New Venture Capital), ZJU-Hangzhou Global Scientific and Technological Innovation Center, and Hangzhou's "Young Eagle Plan", mainly for prototype development and preliminary experiments. In the mid-term stage (Series A), we will seek support from venture capital institutions such as Hillhouse Capital and Sequoia China, as well as strategic investments from pharmaceutical companies such as Huadong Medicine. The funds will be used for clinical trials and production line construction. In the later stage (Series B and IPO), we plan to attract international capital (such as Temasek Holdings) and promote listing on the Science and Technology Innovation Board to support global market expansion and brand internationalization.</p>
                </section>

                <h1>Marketing & implementation</h1>
                <section id="request-analysis">
                    <h2>Analysis of user requests</h2>
                    
                    <h3>Core target group - cataract patients</h3>
                    
                    <div class="content-block">
                        <h4>1. Number of cataract patients</h4>
                        <p>In China, the incidence of cataracts increases significantly with age. According to a study conducted in the suburbs of Shanghai, the incidence of cataracts in the population aged 65 and above was <strong>57.0%</strong>. Another study showed that the incidence of cataracts in the population aged 45 and above in rural western China was <strong>45.15%</strong><sup><a href="#ref1">[1]</a>-<a href="#ref2">[2]</a></sup>.</p>

                        <h4>2. Surgical coverage</h4>
                        <p>In China, the coverage rate of cataract surgery is still low. According to a national study, the proportion of cataract surgery between 2011 and 2015 was only <strong>1.22%</strong>. In the suburbs of Shanghai, the coverage rate of cataract surgery among people aged 65 and above is <strong>10.9%</strong>. In rural areas of the southwest, the cataract surgery coverage rate (CSC) is <strong>53.3%</strong>, but there are still a large number of patients who have not undergone surgery<sup><a href="#ref3">[3]</a> <a href="#ref4">[4]</a></sup>. What's more, there exists an apparent inequality in access, below is the figure that shows the distribution of cataract surgeons per 50,000 population in China in 2014.<sup><a href="#ref10">[10]</a></sup></p>

                        <figure>
                            <img src="../../static/img/hp-entre/map.png" alt="Distribution of cataract surgeons per 50,000 population in China" style="width: 60%;">
                            <figcaption>Distribution of cataract surgeons per 50,000 population across China (2014)</figcaption>
                        </figure>

                        <h4>3. Prevalence of dry eye syndrome among contact lens users</h4>
                        <p>Dry eye syndrome has a high incidence in China. According to a multicenter cross-sectional study, the incidence of dry eye syndrome has significantly increased among contact lens wearers. The study showed that the incidence of dry eye syndrome increased significantly among users who wore contact lenses for more than 3 years<sup><a href="#ref5">[5]</a></sup>.</p>
                        
                        <h3>Urgent needs and existing pain points:</h3>
                        <p>The high cost of cataract surgery and the uneven distribution of medical resources are indeed major issues. The low absorption rate of traditional eye drops (< 5%) and the need for frequent use (6-8 times a day) are also significant pain points.</p>
                    
                    </div>
                </section>

                <section id="marketing-strategy">
                    <h2>Marketing strategy</h2>
                    <!-- Content sections will go here -->
                </section>

                <section id="implementation">
                    <h2>Implementation strategy</h2>
                    <!-- Content sections will go here -->
                </section>



                <section id="references">
                    <h1>Reference</h1>
                    <div class="reference-list">
                        <div class="reference-item" id="ref1">
                            <span class="ref-number">[1]</span>
                            <span class="ref-content">Zhang S, Chen J, Yang F, et al. Prevalence rates of cataract and cataract surgery in elderly Chinese people living in suburban Shanghai: the Pujiang Cataract Cohort Study. <em>Br J Ophthalmol</em>. 2023;107(5):683-689.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/35086805/" class="ref-link" target="_blank">DOI: 10.1136/bjophthalmol-2021-319991</a>
                        </div>
                
                        <div class="reference-item" id="ref2">
                            <span class="ref-number">[2]</span>
                            <span class="ref-content">Du K, Guan H, Zhang Y, et al. Knowledge of cataracts and eye care utilization among adults aged 50 and above in rural Western China. <em>Front Public Health</em>. 2022;10:1034314.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36457322/" class="ref-link" target="_blank">DOI: 10.3389/fpubh.2022.1034314</a>
                        </div>
                
                        <div class="reference-item" id="ref3">
                            <span class="ref-number">[3]</span>
                            <span class="ref-content">Jan C, Xin J, Dong Y, et al. Patterns and determinants of incident cataract surgery in China from 2011 to 2015 using a nationally representative longitudinal database. <em>BMJ Open</em>. 2023;13(6):e069702.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/37344116/" class="ref-link" target="_blank">DOI: 10.1136/bmjopen-2022-069702</a>
                        </div>
                
                        <div class="reference-item" id="ref4">
                            <span class="ref-number">[4]</span>
                            <span class="ref-content">Shen W, Cun Q, Zhong H, et al. Ethnic variation in prevalence, self-reported barriers and outcome of cataract surgery in a rural population in southwestern China. <em>BMC Public Health</em>. 2020;20(1):893.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/32517668/" class="ref-link" target="_blank">DOI: 10.1186/s12889-020-09009-5</a>
                        </div>
                
                        <div class="reference-item" id="ref5">
                            <span class="ref-number">[5]</span>
                            <span class="ref-content">Yang W, Wang H, Li J, et al. Demographic and lifestyle factors associated with dry eye disease in China: A cross-sectional multi-center study. <em>Ocul Surf</em>. 2024;34:146-155.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/39074684/" class="ref-link" target="_blank">DOI: 10.1016/j.jtos.2024.07.007</a>
                        </div>
                
                        <div class="reference-item" id="ref6">
                            <span class="ref-number">[6]</span>
                            <span class="ref-content">Hashemi H, Fayaz F, Hashemi A, et al. Global prevalence of cataract surgery. <em>Curr Opin Ophthalmol</em>. 2025;36(1):10-17.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/39638415/" class="ref-link" target="_blank">DOI: 10.1097/ICU.0000000000001092</a>
                        </div>
                
                        <div class="reference-item" id="ref7">
                            <span class="ref-number">[7]</span>
                            <span class="ref-content">Yang Y, Lockwood A. Topical ocular drug delivery systems: Innovations for an unmet need. <em>Exp Eye Res</em>. 2022;218:109006.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/35248559/" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2022.109006</a>
                        </div>
                
                        <div class="reference-item" id="ref8">
                            <span class="ref-number">[8]</span>
                            <span class="ref-content">Hu J, Ma Q, Xin C, Jiao Y. Analysis of Drug Clinical Trials for Eye Diseases in China. <em>J Ocul Pharmacol Ther</em>. 2022;38(9):645-653.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36264174/" class="ref-link" target="_blank">DOI: 10.1089/jop.2021.0126</a>
                        </div>
                
                        <div class="reference-item" id="ref9">
                            <span class="ref-number">[9]</span>
                            <span class="ref-content">Chauhan A, Fitzhenry L, Serro AP. Recent Advances in Ophthalmic Drug Delivery. <em>Pharmaceutics</em>. 2022;14(10):2075.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36297511/" class="ref-link" target="_blank">DOI: 10.3390/pharmaceutics14102075</a>
                        </div>
                
                        <div class="reference-item" id="ref10">
                            <span class="ref-number">[10]</span>
                            <span class="ref-content">An L, Jan CL, Feng J, et al. Inequity in Access: Cataract Surgery Throughput of Chinese Ophthalmologists from the China National Eye Care Capacity and Resource Survey. <em>Ophthalmic Epidemiology</em>. 2019;27(1):29-38.</span>
                            <a href="https://doi.org/10.1080/09286586.2019.1678654" class="ref-link" target="_blank">DOI: 10.1080/09286586.2019.1678654</a>
                        </div>
                    </div>
                </section>
            
            </div>
        </div>

        <!-- Footer -->
        <footer id="footer">
            <div class="logo_wrap">
                <img id="team_logo" src="../../static/img/Logo-round-text.svg" alt="">
            </div>
            <div class="follow">
                <div class="title">Follow Us</div>
                <ul class="follow_list">
                    <li><a href="https://space.bilibili.com/700401359?spm_id_from=333.337.search-card.all.click" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-bilibili.png" alt=""></a></li>
                    <li><a href="https://twitter.com/ZjuChina" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-twitter.png" alt=""></a></li>
                    <li><a href="https://mp.weixin.qq.com/s/yTMIiH4AQ2skqP-7cXr7Ig" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-wechat.png" alt=""></a></li>
                </ul>
            </div>
            <div class="contact">
                <div class="title">Contact Us</div>
                <div class="email">ZJU_China@outlook.com</div>
            </div>
        </footer>

        <script src="../../static/js/basic.js"></script>
        <script src="../../static/js/pages.js"></script>
        <script src="../../static/js/pdbviewer.js"></script>
        <script src="../../static/js/components.js"></script>
    </body>
</html>